Titan Biotech Announces 1:4 Bonus Share Issue

Bonus Ratio: 1:4 (1 new share for every 4 held)
Capital Increase: Authorised capital raised from Rs 10 crore to Rs 10.40 crore

Reader Takeaway: Bonus issue increases liquidity for long-term holders; watch for the forthcoming record date announcement.

What just happened

Titan Biotech has formally recommended a 1:4 bonus share issue, distributing approximately 1.03 crore new equity shares to eligible shareholders. This issuance will be funded through the company's existing securities premium and free reserves, which stood at Rs 16,257.78 lakh as of March 31, 2026. The move requires a total capitalization of Rs 2.06 crore. To accommodate the increase in issued capital, the board has approved raising the firm's authorised share capital from Rs 10 crore to Rs 10.40 crore, pending shareholder approval at the next AGM.

Why this matters

A bonus issue typically improves trading liquidity for retail investors by increasing the total share count and adjusting the price per share. For existing shareholders, this reflects the company's confidence in its reserve position and ongoing growth strategy. The company has also re-appointed Mr. Rohit Jain as an Independent Director for a second five-year term, signaling continuity in its corporate governance structure.

What changes now

The company is gearing up for its 34th Annual General Meeting, which will take place on September 29, 2026, via video conferencing. Investors must note that September 22, 2026, serves as the cut-off date for voting eligibility and the record date for the previously approved dividend of Rs 0.50 per share. The record date for the bonus issue itself will be announced separately by the company in due course.

What to track next

Shareholders should monitor upcoming announcements regarding the specific record date for the bonus issue. Once confirmed, this date will determine eligibility for receiving the bonus shares, which are expected to be dispatched or credited by November 3, 2026.